Company Abpro Corporation

Abpro Corporation, incorporated on August 18, 2004, is a biotechnology company that is engaged in developing antibody therapeutics. The Company is focused on antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. With the Company's Divers Immune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. The Company? s DiversImmune and MultiMab platforms and licensing strategy has generated a wide range pipeline of antibody product candidates, that includes ABP-100, ABP-110, ABP-130, ABP-300, ABP-500, ABP-201, ABP-200, and ABP-400. The Company's lead candidate, ABP-100, is a immuno-oncology TetraBi antibody that targets human epidermal growth factor receptor 2 (HER2) and cluster of differentiation 3 (CD3) for the treatment of HER2+ solid tumors, including breast, gastric, and endometrial cancers.